¹ GRADING prognostic factors for severe and recurrent

² Clostridioides difficile infection: expected and unexpected

³ findings. A systematic review.

- 4
- Tessel M. van Rossen¹*#, Rogier E. Ooijevaar²*#, Christina M.J.E. Vandenbroucke-Grauls^{1,3}, Olaf M.
 Dekkers⁴, Ed. J. Kuijper⁵, Josbert J. Keller^{6,7}, Joffrey van Prehn⁵
- 7
- 8 ¹ Amsterdam UMC, VU University Medical Center, Medical Microbiology & Infection Control,
- 9 Amsterdam Infection & Immunity, Amsterdam, The Netherlands
- ² Amsterdam UMC, VU University Medical Center, Gastroenterology & Hepatology, Amsterdam
- 11 Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands
- 12 ³ Aarhus University, Clinical Epidemiology, Aarhus, Denmark
- 13 ⁴ Leiden University Medical Center, Clinical Epidemiology, Leiden, The Netherlands
- ⁵ Leiden University Medical Center, Center for Infectious Diseases, Medical Microbiology, Leiden, The
 Netherlands
- ⁶ Haaglanden Medical Center, Gastroenterology & Hepatology, the Hague, the Netherlands
- ⁷ Leiden University Medical Center, Gastroenterology & Hepatology, Leiden, the Netherlands
- 18
- 19 *Both authors contributed equally and should be considered first author
- 20 # Address correspondence to Tessel M. van Rossen, Amsterdam UMC locatie VUmc, PK 2X132, De
- Boelelaan 1117, Amsterdam, the Netherlands, t.vanrossen@amsterdamumc.nl, telephone number:
 0031-204440799.
- 23 Or
- 24 Rogier E. Ooijevaar, Amsterdam UMC locatie VUmc, PK 2X132, De Boelelaan 1117, Amsterdam, the
- 25 Netherlands, r.ooijevaar@amsterdamumc.nl, telephone number: 0031-204440799.

26

- 27 Abstract: 300 words
- 28 Manuscript: 3635 words
- 29
- 30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

32

33 Background

34 *Clostridioides difficile* infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide

- 35 a significant burden for both patients and the healthcare system. Treatment consists of oral
- 36 antibiotics. Fidaxomicin, bezlotoxumab and fecal microbiota transplantion (FMT) reduce the number
- of recurrences compared to vancomycin, but are more costly. Identifying patients diagnosed with
- initial CDI who are at increased risk of developing sCDI/rCDI could lead to more cost-effective
- 39 therapeutic choices.
- 40

41 Objectives

- In this systematic review we aimed to identify clinical prognostic factors associated with an increased
 risk of developing sCDI or rCDI.
- 44

45 Methods

- 46 PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched from
- 47 database inception through March, 2021. Study selection was performed by two independent
- 48 reviewers on the basis of predefined selection criteria; conflicts were resolved by consensus. Cohort
- 49 and case-control studies providing an analysis of clinical or laboratory data to predict sCDI/rCDI in
- 50 patients ≥18 years diagnosed with CDI, were included. Risk of bias was assessed with the Quality in
- 51 Prognostic Research (QUIPS) tool and the quality of evidence by the Grading of Recommendations
- 52 Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies. Overview
- tables of prognostic factors were constructed to assess the number of studies and the respective
- 54 direction of an association (positive, negative, or no association).
- 55

56 **Results and conclusions**

- 57 136 studies were included for final analysis. Higher age and the presence of multiple comorbidities
- 58 were prognostic factors for sCDI. Identified risk factors for rCDI were higher age, healthcare-
- 59 associated CDI, prior hospitalization, PPIs started during/after CDI diagnosis and previous rCDI. Some
- 60 variables that were found as risk factors for sCDI/rCDI in previous reviews were not confirmed in the
- 61 current review, which can be attributed to differences in methodology. Risk stratification for
- 62 sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.
- 63
- 64
- 65
- 66
- 67
- 68

69 Background

- 70 Clostridioides difficile infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide
- a significant burden for both patients and the healthcare system(1). Antibiotic treatment with oral
- vancomycin and fidaxomicin are the cornerstone of CDI treatment(2-4). Fidaxomicin reduces the
- 73 number of recurrences compared to vancomycin (5). Bezlotoxumab, a monoclonal anti-Toxin B
- 74 antibody, can be added to oral anti-CDI antibiotic therapy and reduces the number or recurrences in
- 75 patients at high risk to develop rCDI (6). Fecal microbiota transplantation (FMT) is a highly efficacious
- 76 treatment for rCDI, preventing subsequent recurrences, and can lower mortality risk and disease
- 77 burden of sCDI (7, 8).
- 78 The costs of fidaxomicin, bezlotoxumab and FMT are higher compared to those of vancomycin.
- 79 Identifying patients diagnosed with initial CDI who are at an increased risk of developing a severe
- 80 episode or recurrences could lead to more cost-effective therapeutic choices. Identifying patients at
- 81 risk, however, is challenging. Several prediction models have been developed (9-30), yet none has
- 82 been widely adopted in clinical practice.

83 Objectives

- 84 In this systematic review we aimed to identify clinical prognostic factors associated with an increased
- 85 risk of developing sCDI or rCDI.

86 Methods

87 Data sources

- 88 Two searches were performed to identify risk factors for (1) sCDI and (2) rCDI. The search terms and
- 89 strategy were constructed by a trained librarian, see **Supplementary data**. PubMed, Embase,
- 90 Emcare, Web of Science and COCHRANE Library databases were searched on October 4th, 2019. An
- 91 update of the search was performed on March 13th, 2021. The search was restricted to articles
- 92 published in English. Meeting abstracts were not considered. The search was not limited by year of
- 93 publication. References of key papers were assessed for relevant papers.

94 Study eligibility criteria

- 95 Study eligibility was assessed in a two-step selection process. Two independent reviewers screened
- title and abstract for potentially eligible articles (TvR and RO); discrepancies were resolved by
- 97 consensus. Full-text articles were retrieved for eligibility; data extraction and risk of bias assessment
- 98 of included studies was performed by two researchers (TvR and RO).
- 99 Inclusion criteria: prospective and retrospective cohort and case-control studies including patients
- 100 ≥18 years, diagnosed with CDI, and providing an analysis of clinical or laboratory data to predict
- 101 severe/recurrent CDI.
- 102 Exclusion criteria: study in specific patient populations with a distinct medical condition other than
- 103 CDI (e.g. study population comprises only hemodialysis patients), and small studies (less than 30
- 104 patients with severe/recurrent CDI). Laboratory values that were studied as prognostic factors, but
- 105 which are not part of the regular work-up in CDI (e.g. assays for specific cytokines). Variables that are
- 106 part of (some of) the definitions of sCDI (such as leukocytosis) were excluded as prognostic factor for
- scDI to avoid circularity.

- 108 Studies on prognostic factors with conflicting results in the uni- and multivariable or with
- 109 contradicting results when compared to previous meta-analyses, were assessed and graded by a
- 110 third researcher (CV-G and JK) and scrutinized by weighing the results by the quality of evidence per
- 111 study.
- 112 Outcomes of interest were:
- 113 1. Severe CDI:
- 114a.ESCMID 2014/2021 definition: an episode of CDI with (one or more specific signs and115symptoms of) severe colitis or a complicated course of disease, with significant systemic116toxin effects and shock, resulting in need for ICU admission, colectomy or death (3, 31,11732); or:
- b. IDSA/SHEA definition: an episode of CDI with a white blood cell count of ≥15x10^9
 cells/mL or a serum creatinine level >1.5 mg/dL or increase of 50% or greater from
 baseline(33); or:
- 121 c. Any other author-constructed definition of severe/complicated/fulminant/fatal CDI.
- Recurrent CDI: Recurrence is a new episode of CDI within 2-12 weeks after a previous episode, provided the symptoms of the previous episode resolved after completion of initial treatment (34, 35).
-

126 Assessment of risk of bias

- 127 Risk of bias was assessed with the Quality in Prognostic Research (QUIPS) tool (36), which is
- recommended by the Cochrane Prognosis Methods Group. The QUIPS tool appraises six domains: (1)
- 129 study participation, (2) study attrition, (3) prognostic factor measurement, (4) outcome
- 130 measurement, (5) study confounding and (6) statistical analysis and reporting. The overall risk of bias
- 131 per study is scored as low, moderate, or high.

132 Quality assessment and data synthesis

- 133 The quality of evidence per study was assessed by using the Grading of Recommendations
- 134 Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies (Figure 1)
- 135 (37). This tool is recommended by the Cochrane Prognosis Methods Group and consists of eight
- domains. The starting point for the quality of evidence is based on the phase of investigation. The
- 137 quality can be up- or downgraded according to seven other domains. The QUIPS score is included in
- the second domain ('Study limitations/risk of bias') of the GRADE tool. The outcome of this
- assessment is the quality of evidence per study, which can be very low (+), low (++), moderate (+++)
- 140 or high (++++).
- 141 Overview tables of prognostic factors were constructed to assess the number of studies and the
- 142 respective direction of an association, i.e. positive, negative, or no association based on effect
- 143 estimates, 95% CI intervals and p values, stratified by univariate and multivariate analyses. Similar
- 144 prognostic factors (e.g. coronary artery disease and myocardial infarction) were combined to one
- 145 factor for a more compact overview. No formal meta-analyses were performed.

| 8 domains | | Score | |
|---|--|-----------------|-------------------------------|
| 1. Phase of investigation Quality of evidence: | 1=association / 2=independent association / 3=underlying mechanism + very low / ++ low / +++ moderate / ++++ high | 1/2/3 +-++++ | Quality of |
| 2. Study limitations | risk of bias (QUIPS) | √/× 🖌 | evidence is up- |
| 3. Inconsistency | heterogeneity in results across studies | √/X | or downgraded depending on |
| 4. Indirectness | subset of population of interest/prognostic factor/outcome | \sqrt{X} | domains 2-8 |
| 5. Imprecision | sample size (calculation), $\geq\!10$ patients with outcome per prognostic factor | \sqrt{X} | |
| 6. Publication bias | factor is repetitively investigated, ideally by phase 2-3 studies | \sqrt{X} | |
| 7. Effect size | moderate/large similar effect is reported by most studies | \sqrt{X} | |
| 8. Dose-effect | (continuous/ordinal variables) | \sqrt{X} | |

146 147

7 **Figure 1.** Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, modified for

prognostic studies. The final outcome is the overall quality of evidence per study, which can be very low (+), low
(++), moderate (+++) or high (++++).

150

151 Results

152 The search for prognostic factors for sCDI yielded 1242 references; 126 studies were assessed in

more detail and 76 were included for analysis (20, 24, 25, 29, 38-109); twelve more studies retrieved

154 from cross-references were also included (110-121) resulting in 88 studies for final analysis (Figure


155 **2)**. The search for prognostic factors for rCDI yielded 1104 references; 105 studies were assessed in

more detail and 36 were included for analysis (9, 10, 12-15, 102, 109, 122-149) as were seven studies

157 from cross-references.) (111, 150-155). This resulted in 43 studies for final analysis (Figure 2).

158 Additionally, data of the pivotal RCTs on fidaxomicin and bezlotoxumab were used to support

159 findings (156-160).



160 161

Figure 2. Flow diagram of the selection process of studies on prognostic factors for severe/recurrent CDI

162 Prognostic factors for severe CDI

163 The overall quality of evidence ranged from very low to moderate, mainly due to the retrospective

- nature and small sample size of most studies. The prognostic factors studied in five or more articlesare shown in **Table 1**.
- 166 Age was the most studied prognostic factor, and was investigated in 53 of 88 included studies (20,

167 24, 25, 29, 38-42, 44, 46-49, 52, 54, 55, 57, 59, 61-64, 66, 70, 71, 75, 77, 78, 80, 81, 83, 85-88, 91-94,

- 168 96, 97, 100, 104, 106, 109-111, 113, 114, 116-118). Fifty-one studies performed a univariate analysis
- and 40 studies (also) a multivariable analysis; 37/51 studies reported *higher age* as risk factor for
- scDI in univariate analysis, and 26/40 studies in multivariable analysis (overall moderate quality of
- 171 evidence).
- 172 Thirty-two studies assessed the presence of *multiple comorbidities* as risk factor for sCDI (25, 38-42,
- 46-49, 52, 62, 66, 70, 72-74, 80, 81, 85, 87, 88, 91-94, 96, 97, 109, 114, 116, 117); 20/30 studies
- 174 found an association between the presence of *multiple comorbidities* and sCDI in univariate analysis
- 175 and 11/23 studies in multivariable analysis (moderate quality of evidence).
- 176 For both higher age and the presence of multiple comorbidities a dose effect was observed: the
- 177 higher the age or the more concurrent disorders, the higher the risk of severe disease. No specific
- 178 medical condition was associated with sCDI.
- 179 For clinical decision making, a specific cut-off value for age and number of comorbidities would be
- 180 convenient. However, in many studies age was used as a continuous variable (31/53 studies) or
- 181 varying cut-off values are used. The majority of studies found a higher risk for sCDI in patients older
- 182 than 65-70 years. For comorbidity, different established or self-constructed comorbidity scores were
- reported, the Charlson Comorbidity Index (CCI) most frequently (161). Again, most studies used CCI
- as continuous variable. Of the studies that identified more comorbidities as risk factor for sCDI, only
- three used a cut-off value: one study reported a higher risk in patients with a CCI of \geq 3, and two
- 186 found a higher risk in patients with ≥2 comorbidities (88, 93, 96). Thus, no statement can be made on
- 187 the association between exact numbers of comorbidities and severe CDI.
- 188 Twenty articles studied the association between the presence of NAP1/RT027 strain and sCDI (44-46,
- 189 56, 60, 61, 73, 74, 81, 84, 85, 88, 89, 91, 94, 96, 100, 101, 108, 111); 8/19 studies reported a higher
- risk of sCDI in patients with NAP1/027 strain in univariate analysis, and 5/10 in multivariate analysis.
- 191 One study found that NAP1/027 was more prevalent in patients with mild disease compared to
- 192 patients with sCDI (44).
- 193 Furthermore, seven studies assessed *C. difficile* binary toxin as risk factor for sCDI (45, 82, 91, 94,
- 194 117, 119, 121). Of these, three identified *C. difficile* binary toxin as a risk factor for sCDI in univariate
- analysis, and only 1/1 study in multivariate analysis. The overall quality of evidence of these studies
- 196 was low. We scrutinized the separate studies on the presence of NAP1/RT027 strain and/or binary
- toxin by weighing the results by the quality of evidence per study, but this did not alter the
- 198 conclusion.
- 199 Another interesting finding was that the majority of studies did not find an association between the
- 200 use of *PPIs, H2 receptor antagonists* or *antibiotics* and the occurrence of sCDI in uni- and multivariate
- 201 analyses. However, the quality of evidence was low.

- 202 In conclusion, only the factors *higher age* (>65-70 years old) and the presence of *multiple*
- 203 *comorbidities* were consistently associated with sCDI (**Table 3**).

| Potential prognostic Number of factor participar | | Number | Univariate | | | Multivariab e | | | GRADE factors | | | | | | | | | | |
|--|---------------------------|---------------|------------|----|----|------------------|----|----|---------------|----------------------|---------------|--------------|--------------|---------------------|-----------------------------------|----------------|---------------------------|--|--|
| | Number of participants | of studies | + | 0 | - | + | 0 | - | Phase | Study limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Moderate/ large effect size | Dose effect | Quality of evidence | | |
| Demographics | | | | | | | | | | • | L | | • | | | | | | |
| Higher age | 4,240,336 | 53 | 37 | 14 | 0 | 26 | 14 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | \checkmark | \checkmark | +++ | | |
| Gender* | 4,224,842 | 40 | 6M | 31 | 2F | 2M | 12 | 2F | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| Caucasian ethnicity | 1,266,818 | 9 | 2 | 7 | 0 | 1 | 3 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| Comorbidities | | | | | | | | | | | | | | | | | | | |
| More comorbidities | 4,213,584 | 32 | 20 | 10 | 0 | 11 | 12 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | \checkmark | \checkmark | +++ | | |
| Cardiovascular | 1,287,293 | 19 | 8 | 10 | 0 | 5 | 7 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| Pulmonary | 1,345,420 | 16 | 6 | 9 | 0 | 3 | 6 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Neurological | 88,881 | 11 | 1 | 8 | 1 | 1 | 4 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| ADL dependency | 4,261 | 6 | 4 | 1 | 0 | 2 | 3 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | \times | + | | |
| Infection | 4,900 | 7 | 3 | 3 | 0 | 1 | 3 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Malignancy | 1,346,642 | 21 | 7 | 13 | 0 | 4 | 5 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Chronic renal disease | 2,875,427 | 24 | 7 | 16 | 0 | 6 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Liver disease | 1,343,798 | 11 | 2 | 8 | 0 | 2 | 3 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Inflammatory bowel disease | 79,856 | 6 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Diabetes mellitus | 1,357,184 | 24 | 4 | 16 | 3 | 2 | 8 | 2 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Immunocompromised | 95,665 | 26 | 9 | 17 | 0 | 6 | 6 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Under- or overweight~ | 1,263,658 | 6 | 1 | 6 | 0 | 1 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Medication | | | | | | | | | | | | | | | | | | | |
| Acid suppression/peptic ulcer disease | 83,876 | 11 | 4 | 7 | 0 | 3 | 3 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| PPIs | 8,521 | 17 | 3 | 14 | 0 | 0 | 4 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| H2 receptor antagonists | 4,564 | 9 | 2 | 7 | 0 | 1 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Antibiotic use¶ | 11,985 | 24 | 4 | 19 | 0 | 3 | 5 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |
| Fluoroquinolones | 4,053 | 9 | 1 | 8 | 0 | 0 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | X | × | ++ | | |
| Antiperistaltics | 2,559 | 5 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| Recent medical history | | | | | | | | | | | | | | | | | | | |
| Previous surgery | 10,433 | 8 | 2 | 6 | 0 | 1 | 1 | 0 | 1 | \times | \checkmark | \checkmark | \checkmark | \checkmark | × | \times | ++ | | |
| Malnutrition/(par)entera I feeding CDI factors | 4,190 | 8 | 2 | 6 | 0 | 1 | 3 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | |

| Healthcare facility associated | 13,677 | 30 | 10 | 20 | 0 | 2 | 10 | 0 | 1 | Х | \checkmark | \checkmark | \checkmark | ×^ | × | × | + |
|-----------------------------------|-----------|----|----|----|---|---|----|---|---|--------------|--------------|--------------|--------------|--------------|---|---|----|
| Community associated | 3,093 | 6 | 1 | 5 | 0 | 0 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | X | × | ++ |
| NAP1/027 strain | 10,141 | 20 | 8 | 10 | 1 | 5 | 4 | 1 | 2 | × | × | \checkmark | \checkmark | \checkmark | X | × | ++ |
| Binary toxin | 3,836 | 7 | 3 | 5 | 0 | 1 | 0 | 0 | 2 | \checkmark | ×\$ | \checkmark | \checkmark | \checkmark | × | X | ++ |
| Positive toxin EIA | 9,642 | 9 | 6 | 3 | 0 | 3 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | X | ++ |
| Prior CDI (>3 months) | 2,341 | 5 | 0 | 5 | 0 | 0 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | X | ++ |
| Recurrent CDI (<3 months) | 12,842 | 5 | 3 | 2 | 0 | 1 | 1 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | + |
| Laboratory values | | | | | | | | | | | | | | | | | |
| Anemia | 6,121 | 9 | 4 | 5 | 0 | 2 | 3 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | X | × | + |
| Thrombocytopenia | 5,125 | 6 | 4 | 2 | 0 | 2 | 2 | 0 | 1 | × | × | \checkmark | \times | \checkmark | × | X | + |
| Electrolyte imbalance | 1,263,366 | 3 | 3 | 0 | 0 | 1 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | + |

Table 1. Potential prognostic factors for severe CDI. Phase, phase of investigation. For uni- and multivariate analyses: +, number of significant effects with a positive value; 0, number of non-significant effects; -, number of significant effects with a negative value. For GRADE factors: \checkmark , no serious limitations; X, serious limitations (or not present for moderate/large effect size, dose effect); unclear, unable to rate item based on available information. For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high.

* *M* = male; *F* = female. In 4 studies male gender and in 2 studies female gender was identified as prognostic factor for severe CDI in univariate analysis. In multivariate analysis, 2 studies reported male gender and 2 studies reported female gender as risk factor of sCDI.

~ One study analyzed both under- and overweight as prognostic factors for sCDI; this study identified underweight but not overweight as risk factor for sCDI in uni- and multivariate analyses.

¶ Besides from antibiotic use (yes/no) prior to CDI diagnosis, none of the following separate antibiotic class was found to be predictive of sCDI: cephalosporins (n=7 studies), penicillins (n=4), macrolides (n=4), glycopeptides (n=3). Results for carbapenems were inconsistent with a tendency towards 'no effect' (n=8).

^ Publication bias is probable since most prognostic studies for sCDI are performed in hospitalized patients

Seven studies assessed the presence of C. difficile binary toxin as prognostic factor for sCDI. Of these, one study contained two cohorts: in univariate analysis, binary toxin was associated with sCDI in one cohort, but not in the other cohort (121). Both results are reported in the results columns of the univariate analyses. Therefore, in this table the number of studies on binary toxin is 7, but the total number of univariate analyses is 8.

\$ One large prospective study (Berry et al) and one small prospective study (López-Cárdenas) found binary toxin as risk factor for severe CDI and/or mortality; one large retrospective study (Carlson et al) found that the combination of binary toxin and eosinopenia was associated with mortality; two smaller prospective studies and two retrospective studies did not identify binary toxin as risk factor for sCDI.

204 Prognostic factors for recurrent CDI

The overall quality of evidence for the prognosis of recurrent CDI (rCDI) was low to moderate (Table
206 2). The majority of studies was retrospective, with a high to moderate risk of bias.

207 *Higher age (≥65 years old)* is the most studied factor and was investigated in 35/43 included studies
208 (9, 10, 12-15, 109, 111, 122, 123, 125, 126, 128, 130-134, 136-141, 143-153), 15/30 studies identified

higher age as risk factor for rCDI in univariate analysis, and 16/31 studies in multivariable analysis.

210 Moreover, higher age was the only factor for which we found a moderate to large effect size and a

- 211 dose-dependent effect.
- 212 Eight studies assessed whether a previous CDI recurrence in the preceding 3 months was a risk factor
- for a subsequent rCDI, and showed inconsistent results (9, 10, 15, 111, 125, 133, 140, 145). Two
- 214 prospective studies of higher quality found a clear association of previous recurrence with the risk of
- a subsequent rCDI (111, 140). Also, data of the pivotal trials on fidaxomicin and bezlotoxumab
- 216 indicate that recurrence rates are higher in patients with any previous CDI episode or patients that
- 217 fulfill criteria for rCDI (156-160). Since these trials are considered high quality studies, we have
- 218 upgraded the level of evidence from low to moderate (Table 3). Finally, we consider two or more
- 219 episodes of CDI as risk factor for a subsequent rCDI.
- 220 Healthcare-acquired CDI was associated with rCDI in univariate analyses of 5/10 studies, and in
- 221 multivariable analyses of 2/4 studies (9, 14, 111, 125, 128, 141, 144, 145, 149, 150). This is also
- reflected by the correlation of *prior hospitalization (<3 months)* with a recurrent episode of CDI (13,
- 15, 125, 128, 133, 138, 143, 149). The two largest cohort studies showed a significant association
- between prior hospitalization and rCDI in uni- and multivariable analysis (128, 149). Of note, one
- 225 large cohort study reported a protective effect of community-acquired CDI for the development of
- 226 rCDI (128).

227 *Proton pump inhibitor use* was studied in 23 included studies (9, 13, 14, 109, 122, 123, 130-135, 137,

- 139, 141, 145, 147-151, 153, 155). The results show no clear association between PPIs and rCDI in
 univariate analyses, while in multivariable analyses there appears to be an association. Of note, some
- 230 studies made a distinction between the moment PPI was started, i.e. prior to initial CDI episode or
- during/shortly after the initial episode (12, 13, 15, 123, 125, 146, 149, 155); PPI prescribed during or
- shortly after initial CDI appears to be associated with an increased risk of rCDI (effect found in 6/7
- studies in univariate analysis, and in 2/4 studies in multivariable analysis; low quality of evidence).
- 234 Eight studies reported on *non-CDI antibiotic use* after initial CDI diagnosis as a risk factor, but results
- were inconsistent (12, 123, 129, 136, 141, 145, 146, 148); 4/6 studies found an association between
- 236 non-CDI antibiotic use and rCDI in univariate analysis, and 2/5 studies in multivariable analysis. A
- high-quality prospective study showed no significant association between antibiotic use and rCDI in
- both uni- and multivariate analysis (136). Several other studies investigated whether specific
- antibiotics that incited the primary CDI episode, were associated with recurrence; none of these
- antibiotic drugs was associated with rCDI. In conclusion, nor non-CDI antibiotic use prior to the
- primary CDI, nor concomitant non-CDI antibiotics used during the primary CDI episode, appeared to
- 242 be convincing predictors for rCDI.
- Although various definitions of sCDI are used in prognostic studies, most studies did not find severity of CDI to be a prognostic factor for rCDI (9, 123, 126, 131, 134, 140-142, 147, 150); 2/7 studies

- identified sCDI as risk factor for rCDI in univariate analysis, and 2/4 in multivariable analysis. In the
- 246 MODIFY trials, sCDI was a prespecified risk factor for recurrence, but in the placebo arm the
- recurrence rate was lower in the sCDI subgroup (22.4%) than in the non-CDI subgroup (27.5%) (158).
- 248 Since we expected sCDI to be a risk factor for rCDI, re-assessment of included studies was performed
- by a third researcher (CV-G); this did not alter our results. In conclusion, we found insufficient
- evidence to consider sCDI a risk factor for rCDI.
- 251 Several studies investigated specific comorbidities, including chronic renal failure, diabetes mellitus,
- 252 and cardiovascular disease as risk factors for rCDI (9, 12-15, 111, 122, 123, 125, 126, 128, 130-134,
- 253 136, 138-154). Our review does not show any of these comorbidities to be clearly associated with an
- increased risk for rCDI. Even when combined into a robust score such as the Charlson Comorbidity
- 255 Index, we did not identify a clear association (13, 65, 122, 130, 132-134, 140, 145, 146, 148, 150,
- 256 152). Since results of the uni- and multivariable analyses of studies reporting in renal failure were
- 257 conflicting, these studies were re-assessed by a third researcher. This led to identical findings.
- 258 Immunocompromised status was a prespecified risk factor in the MODIFY trials; though in the
- 259 placebo arm the recurrence rate in immunocompromised patients did not differ from that in
- 260 immunocompetent patients (27.5% vs 26.6%) (158). A post-hoc analysis of the pivotal fidaxomicin
- trials investigated fever, leukocytosis and renal failure as prognostic markers, and identified renal
- failure as the only significant predictor for recurrence (RR, 1.45; 95% CI, 1.05–2.02). Overall, we
- 263 found insufficient evidence to consider other comorbidities a risk factor for rCDI.
- 264 The ribotype 027 strain was not clearly associated with recurrence. However, only five studies
- reported on this ribotype as a possible risk factor (111, 123, 129, 145, 148); 2/5 studies found that
- the presence of a RT027 strain was associated with sCDI in univariate analysis, and only 1/3 studies in
- 267 multivariable analysis. Since these results were inconsistent when compared to a previous systematic
- review, results were re-assessed by a third researcher (162). This reassessment did not result in
- 269 different conclusions.
- 270 Laboratory parameters studied include white blood cell counts, and levels albumin, creatinine and C-
- reactive protein. None of these parameters was clearly associated with rCDI (10, 12-15, 111, 134,
 141, 144-147, 149).
- 273 Our findings show the use of probiotics as prophylaxis for CDI seemed to be associated with rCDI (13,
- 14, 123, 133). However, this association is based on a small number of studies (n=4) and might be
- confounded by the fact that probiotics are started in patients with a high risk of rCDI and/or
- concomitant antibiotic use.

| | | | U | nivari | /ariate | | ltivar | iable | | | | | GRADE factors | GRADE factors | | | | | | | | | |
|---|---------------------------|-------------------------|--------|---------|---------|--------|--------|-------|--------|----------------------|---------------|--------------|---------------|---------------------|-----------------------------------|----------------|---------------------|--|--|--|--|--|--|
| Potential prognostic factor identified | Number of participants | Number of studies | + | 0 | - | + | 0 | - | Phase | Study limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Moderate/ large effect size | Dose effect | Quality of evidence | | | | | | |
| Demographics | • | • | | | | | | | | | | • | | | | | | | | | | | |
| Higher age | 52,312 | 35 | 15 | 15 | 0 | 16 | 5 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | \checkmark | \checkmark | +++ | | | | | | |
| Gender | 7,074 | 8 | 0 | 7 | 0 | 0 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Male | 15,769 | 10 | 2 | 7 | 0 | 1 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Female | 5,833 | 12 | 2 | 9 | 0 | 1 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Community-acquired CDI | 13,837 | 7 | 1 | 5 | 1 | 1 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Hospital-acquired CDI | 10,468 | 10 | 5 | 5 | 0 | 2 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Caucasian race | 13,335 | 3 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | + | | | | | | |
| CDI factors | | | | | | | | | | | | | | | | | | | | | | | |
| Severe CDI | 8,796 | 10 | 2 | 7 | 0 | 2 | 2 | 0 | 1 | × | \checkmark | \checkmark | × | \checkmark | × | × | + | | | | | | |
| Ribotype 027 strain | 6,921 | 5 | 2 | 3 | 0 | 1 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Recurrent CDI episode (<3 months) | 20,868 | 8 | 2 | 3 | 0 | 3 | 1 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Comorbidities Charlson comorbidity index | 30,045 | 13 | 2 | 7 | 0 | 2 | 4 | 0 | 1 | \sim | / | / | / | / | \checkmark | \sim | ++ | | | | | | |
| Cardiovascular (CHF/MI) | 20,160 | 15 11 | 4 | , 7 | 0 | 2 | 4 1 | 0 | 1 | ×× | \checkmark | \checkmark | √ × | \checkmark | ×× | × × | | | | | | | |
| | | 6 | | | - | | 0 | 0 | | × | × | | × | | × | × | ++ | | | | | | |
| Peripheral vascular disease Cerebrovascular (stroke) | 18,318 17,785 | 6 | 2 2 | 4 4 | 0 0 | 0 0 | 0 | 0 | 1 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | + | | | | | | |
| (Chronic obstructive) Pulmonary disease | 19,908 | 11 | 1 | 4 10 | 0 | 0 | 0 | 0 | 1 | × × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ ++ | | | | | | |
| (Chronic) Renal disease/failure | 26,440 | 19 | 3 | 15 | 0 | 2 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | Х | +++ | | | | | | |
| Diabetes mellitus | 20,745 | 14 | 2 | 12 | 0 | 1 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | +++ | | | | | | |
| Liver disease | 14,378 | 8 | 0 | 8 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Inflammatory bowel disease | 13,977 | 6 | 3 | 3 | 0 | 1 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Dementia | 12,458 | 5 | 1 | 4 | 0 | 0 | 0 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Malignancy | 13,685 | 10 | 0 | - 10 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Solid malignancy | 10,078 | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | + | | | | | | |
| Hospital admission factors | 10,078 | - | 1 | 5 | 0 | U | U | 0 | 1 | ~ | v | v | v | v | ~ | ~ | • | | | | | | |
| Prior hospitalization (<3 months) | 31,952 | 8 | 5 | 2 | 0 | 2 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Requirement of ICU admission | 28,356 | 8 | 2 | 4 | 0 | 0 | 3 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Increased length of stay (>10 days) | 2,464 | 5 | 3 | 2 | 0 | 1 | 2 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | + | | | | | | |
| Medication | | | | | | | | | | | | | | | | | | | | | | | |
| Concomitant non-CDI AB | 7,980 | 8 | 2 | 4 | 0 | 2 | 3 | 0 | 1 | Х | × | \checkmark | \checkmark | \checkmark | × | × | + | | | | | | |
| Proton pump inhibitor | 43,653 | 23 | 6 | 14 | 1 | 8 | 3 | 1 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| PPI prior to CDI | 14,308 | 5 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | + | | | | | | |
| PPI during/after CDI | 11,785 | 7 | 6 | 1 | 0 | 2 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| H2 receptor antagonist | 29,998 | 5 | 2 | 2 | 0 | 2 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |
| Steroids / immunosuppression | 11,429 | 10 | 3 | 6 | 0 | 2 | 3 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ | | | | | | |

| Probiotics | 29,847 | 4 | 3 | 0 | 0 | 2 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
|------------------------|--------|----|---|----|---|---|---|---|---|----------|--------------|--------------|--------------|--------------|----------|---|-----|
| Chemotherapy | 20,494 | 8 | 0 | 7 | 0 | 1 | 1 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | X | × | ++ |
| Parenteral feeding | 2,988 | 7 | 1 | 6 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | × | × | × | + |
| Inciting AB | | | | | | | | | | | | | | | | | |
| Aminopenicilin | 10,435 | 5 | 1 | 4 | 0 | 0 | 0 | 0 | 1 | \times | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Cephalosporin | 4,086 | 4 | 0 | 4 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Fluorquinolones | 15,657 | 12 | 3 | 9 | 0 | 2 | 0 | 0 | 1 | \times | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Aminoglycoside | 10,271 | 4 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | \times | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Clindamycin | 10,679 | 5 | 2 | 3 | 0 | 1 | 0 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | × | × | + |
| Macrolide | 10,435 | 5 | 1 | 4 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Carbapenem/meropenem | 9,938 | 7 | 0 | 7 | 0 | 0 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Laboratory values | | | | | | | | | | | | | | | | | |
| Leukocytes (mean/peak) | 22,954 | 17 | 6 | 10 | 0 | 1 | 3 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | \times | × | ++ |
| Albumin (mean/low) | 18,737 | 12 | 4 | 8 | 0 | 1 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Creatinine (mean/peak) | 19,651 | 14 | 1 | 12 | 0 | 1 | 2 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | \times | × | +++ |
| C-reactive protein | 9,805 | 5 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | × | × | \checkmark | \checkmark | \checkmark | \times | × | + |
| Symptoms | | | | | | | | | | | | | | | | | |
| Fever | 3,740 | 9 | 3 | 6 | 0 | 2 | 0 | 0 | 1 | × | \checkmark | \checkmark | \checkmark | \checkmark | × | × | ++ |
| Abdominal pain | 5,756 | 5 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | Х | × | \checkmark | \checkmark | \checkmark | × | × | + |

Table 2. Potential prognostic factors for recurrent CDI. Phase, phase of investigation. For uni- and multivariate analyses: +, number of significant effects with a positive value; 0, number of non-significant effects; -, number of significant effects with a negative value. For GRADE factors: \checkmark , no serious limitations; X, serious limitations (or not present for moderate/large effect size, dose effect); unclear, unable to rate item based on available information. For overall quality of evidence: +, very low; ++, low; +++, moderate; ++++, high

| Prognostic factor | Quality of evidence |
|---|---------------------|
| Severe CDI | |
| Higher age (>65-70 years old) | moderate |
| Presence of multiple comorbidities | moderate |
| Recurrent CDI | |
| Higher age (>65-70 years old) | moderate |
| Previous recurrence of CDI (<3 months) | moderate |
| Healthcare-associated CDI | low |
| Prior hospitalization (<3 months) | low |
| Proton pump inhibitors started during/after CDI diagnosis | low |

277 **Table 3.** Summary of findings

278 Conclusions

279 In this systematic review, we applied the GRADE methodology to weigh the evidence on prognostic

280 factors for sCDI and rCDI (37). We found that the most important risk factors for sCDI were higher

age (≥65-70 years old) and presence of multiple comorbidities. Higher age was also a prognostic

factor for rCDI. Other factors associated with an increased risk of rCDI were the acquisition of CDI as

a healthcare-associated infectionand prior hospitalization and the start of PPIs during/after CDI

diagnosis. The evidence for having a previous recurrence of CDI as risk factor for rCDI was less strong.

285 Our systematic review on prognostic factors resulted in several expected and unexpected findings

when compared with previous reviews rCDI (162-164). Our findings are in line with two recently
 published systematic reviews on predictors of sCDI that reported age and presence of comorbidities

as the two most important severity predictors for CDI (162, 165). Similarly, previous reviews on

289 prognostic factors for rCDI found that older age, prior CDI and PPI therapy were risk factors for rCDI

290 (162-165). However, PPI therapy in general did not show a clear association in our study.

291 In contrast, we could not clearly identify several previously reported risk factors for sCDI or rCDI, such

as infection caused by a ribotype 027/NAP1 strain, antibiotic use, PPI use prior to CDI diagnosis, and

the presence of chronic or end-stage renal disease (162, 163). One possible explanation might be

that many reviews excluded studies reporting solely univariate analyses. This might lead to an

295 overestimation of the effect of certain prognostic factors, since many studies only include variables

with a significant association in univariate analysis in their multivariable analysis. Another

297 explanation for our findings might be index event bias: this bias arises in studies that select patients

based on the occurrence of an index event, and can lead to 'negative' or even paradoxical findings in

recurrence risk research (166). Here, we found that chronic renal failure did not appear to be

associated with rCDI. Previous research shows that patients with kidney failure are prone to

301 developing a primary CDI, but the direct association between kidney disease and rCDI is less clear

302 (163, 167). Since reviews on rCDI select studies based on the occurrence of a primary CDI, this might

303 explain why renal disease is not a strong predictor of rCDI in previous reviews, and not a significant

304 risk factor in the current review.

- Finally, when studying IBD as prognostic factor for sCDI/rCDI, another difficulty in interpretation
- arises, since symptoms of IBD are similar to those of CDI. Furthermore, patients with IBD are at
- 307 higher risk of CDI and infection and colonization with *C. difficile* can induce an exacerbation of IBD
- 308 (168). Also, diagnostic tests do not always allow to differentiate between *C. difficile* infection or
- 309 colonization. Many clinicians pragmatically start antibiotic treatment in IBD patients without
- endoscopy. Subsequent false-positive CDI diagnoses may contribute to an overestimation of CDI
- 311 (recurrence) risk. Aforementioned factors may have contributed to differences between the results
- 312 of our current review and previous publications.
- 313 Our review has several strengths. First, we used a broad search strategy and included a large number
- of studies, minimizing the risk of missing data. Second, articles were selected based on strict
- predefined criteria by two independent researchers (TvR and RO). Third, the quality of the studies
- 316 was judged by the structured prognostic GRADE approach. To our knowledge this approach has not
- been previously used for prognostic factors for sCDI and rCDI. Also, we reported results of both uni-
- and multivariable analyses. When results of the uni- and multivariable analyses of different studies
- 319 were conflicting, we acknowledged this disparity and results were re-assessed by a third researcher.
- 320 Reassessment was performed on the studies reporting the presence of RT027 strain, sCDI and renal
- 321 disease as possible risk factors for rCDI, but this did not result in different conclusions. Finally, some
- disparity can be explained by the large number of studies where non-significant univariate prognostic
- 323 factors were not included in the multivariate models.
- A limitation is the generally low quality of available studies. Most studies have not performed a
- 325 sample size calculation, allowing for possible type I and type II statistical errors. As many studies
- 326 were retrospective, it was not always clear whether certain factors were already present before the
- 327 occurrence of sCDI/rCDI (i.e. truly prognostic factors) or whether they co-existed. A second important
- 328 limitation is the subjectivity how to weight different quality studies, which also resulted in
- 329 stimulating discussions in our working group.
- 330 Identifying prognostic factors for sCDI and rCDI could aid clinicians to make an optimal treatment
- decision to reduce the risk of recurrent disease and decrease CDI complications. The findings of this
- review are especially relevant for rCDI: a risk stratification strategy may allow for selective use of
- 333 more expensive novel treatments with less risk of recurrence. To implement risk stratification of in
- 334 clinical practice, simple risk tools are needed. Currently, several prediction models or risk scores for
- scDI and rCDI have been developed (9-30). However, none has gained widespread clinical
- implementation. Based on the low quality of the studies and small effects of identified prognostic
- 337 factors, it is not surprising that validation of prediction tools in external cohorts show disappointing
- results (169-171). Additional explanations are the heterogeneity and multimorbidity of the CDI
- population and variation in study setting, diagnostic criteria and CDI treatment regiments. The
- 340 current review may be used as starting point for the development of a risk tool with a better
- 341 performance in the overall CDI population. We suggest that future clinical trials on CDI treatment use
- 342 standardized definitions for recurrence and severity and systematically collect and report the risk
- 343 factors that we have discussed in this review, to allow for meaningful meta-analysis on risk factors
- 344 using data of high-quality trials.
- 345 In conclusion, our approach identified higher age and the presence of multiple comorbidities as
- 346 prognostic factors for sCDI. The only identified risk factors for rCDI were higher age, healthcare-
- 347 associated CDI, prior hospitalization (<3 months), PPIs started during/after CDI diagnosis and rCDI.

- 348 Some variables that were found as risk factors for sCDI/rCDI in previous reviews, were not confirmed
- in the current review, which can be attributed to differences in methodology. Risk stratification for
- 350 sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.

351 Transparency declaration

352 Conflict of interest disclosures, funding

- 353 TvR was supported by Netherlands Organization for Health Research and Development (ZonMw)
- 354 grant *Goed Gebruik Geneesmiddelen*, project number 848016009. JK and EK received a research
- 355 grant from Vedanta Biosciences (Boston, USA). The funders had no role in study design, data
- 356 collection and interpretation, or the decision to submit the work for publication. All other authors: no
- 357 conflicts of interest to disclose.

358 Contribution

- 359 JP and EK conceived the study on behalf of the *ESCMID Study Group for Clostridioides difficile*
- 360 (ESGCD). JP designed the search strategy. TvR and RO selected the studies and acquired the data.
- 361 TvR, RO, CV-G and JK graded selected studies. TvR, RO and OD analyzed the data. TvR and RO drafted
- the manuscript. All authors critically revised the manuscript and approved the final version.

363 References

Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium
 difficile infection in the United States. N Engl J Med. 2015;372(9):825-34.

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice
 Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious
 Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin
 Infect Dis. 2018;66(7):987-94.

Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical M, Infectious D. European
 Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document
 for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Suppl 2:1-26.

Ooijevaar RE, van Beurden YH, Terveer EM, Goorhuis A, Bauer MP, Keller JJ, et al. Update of
 treatment algorithms for Clostridium difficile infection. Clinical microbiology and infection : the
 official publication of the European Society of Clinical Microbiology and Infectious Diseases.
 2018;24(5):452-62.

Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for
 Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis.
 2018;18(9):1035-44.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for
 Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-17.

Janiro G, Masucci L, Quaranta G, Simonelli C, Rizzatti G, Lopetuso L, et al. Randomized Clinical
 Trial: Single-Infusion Fmt Versus Multiple-Infusion Fmt for the Treatment of Severe C. Difficile
 Infection. Digest Liver Dis. 2018;50(2):E66-E7.

- 385 8. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal
 386 infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15.
- Cobo J, Merino E, Martinez C, Cozar-Llisto A, Shaw E, Marrodan T, et al. Prediction of
 recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. Int J Antimicrob Agents.
 2018;51(3):393-8.
- D'Agostino RB, Sr., Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent
 Clostridium difficile infection based on clinical factors. Clin Infect Dis. 2014;58(10):1386-93.

392 11. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Development and validation of a
 393 recurrent Clostridium difficile risk-prediction model. J Hosp Med. 2014;9(7):418-23.

Larrainzar-Coghen T, Rodriguez-Pardo D, Puig-Asensio M, Rodriguez V, Ferrer C, Bartolome R,
 et al. First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis.
 European journal of clinical microbiology & infectious diseases : official publication of the European
 Society of Clinical Microbiology. 2016;35(3):371-8.

Reveles KR, Mortensen EM, Koeller JM, Lawson KA, Pugh MJV, Rumbellow SA, et al.
Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National
Cohort of Veterans. Pharmacotherapy. 2018;38(3):349-56.

401 14. Viswesh V, Hincapie AL, Yu M, Khatchatourian L, Nowak MA. Development of a bedside
402 scoring system for predicting a first recurrence of Clostridium difficile-associated diarrhea. Am J
403 Health Syst Pharm. 2017;74(7):474-82.

Hebert C, Du H, Peterson LR, Robicsek A. Electronic health record-based detection of risk
 factors for Clostridium difficile infection relapse. Infect Control Hosp Epidemiol. 2013;34(4):407-14.

LaBarbera FD, Nikiforov I, Parvathenani A, Pramil V, Gorrepati S. A prediction model for
 Clostridium difficile recurrence. J Community Hosp Intern Med Perspect. 2015;5(1):26033.

Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, et al. Prospective derivation and
validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology.
2009;136(4):1206-14.

411 18. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in
412 Clostridium difficile infection: a systematic review. PloS one. 2012;7(1):e30258.

413 19. Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW. High Horn's index score predicts poor
414 outcomes in patients with Clostridium difficile infection. The Journal of hospital infection.
415 2011;79(1):23-6.

416 20. Bhangu S, Bhangu A, Nightingale P, Michael A. Mortality and risk stratification in patients 417 with Clostridium difficile-associated diarrhoea. Colorectal disease : the official journal of the

418 Association of Coloproctology of Great Britain and Ireland. 2010;12(3):241-6.

Butt E, Foster JA, Keedwell E, Bell JE, Titball RW, Bhangu A, et al. Derivation and validation of
a simple, accurate and robust prediction rule for risk of mortality in patients with Clostridium difficile
infection. BMC Infect Dis. 2013;13:316.

22. Drew RJ, Boyle B. RUWA scoring system: a novel predictive tool for the identification of
patients at high risk for complications from Clostridium difficile infection. The Journal of hospital
infection. 2009;71(1):93-4; author reply 4-5.

425 23. Hensgens MP, Dekkers OM, Goorhuis A, LeCessie S, Kuijper EJ. Predicting a complicated 426 course of Clostridium difficile infection at the bedside. Clin Microbiol Infect. 2014;20(5):O301-8.

427 24. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: a severity index for
428 Clostridium difficile infection at the time of admission. The Journal of hospital infection.
429 2011;79(2):151-4.

430 25. Na X, Martin AJ, Sethi S, Kyne L, Garey KW, Flores SW, et al. A Multi-Center Prospective
431 Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PloS
432 one. 2015;10(4):e0123405.

433 26. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Diseases of the colon434 and rectum. 1995;38(4):350-4.

435 27. Valiquette L, Pépin J, Do XV, Nault V, Beaulieu AA, Bédard J, et al. Prediction of complicated
436 Clostridium difficile infection by pleural effusion and increased wall thickness on computed
437 tomography. Clin Infect Dis. 2009;49(4):554-60.

438 28. Velazquez-Gomez I, Rocha-Rodriguez R, Toro DH, Gutierrez-Nuñez JJ, Gonzalez G, Saavedra S.
439 A Severity Score Index for Clostridium difficile Infection. Infectious Diseases in Clinical Practice.

440 2008;16(6):376-8.

441 29. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as

442 predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score.

The Journal of hospital infection. 2011;79(4):359-63.

444 30. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. Clostridium difficile-associated 445 disease and mortality among the elderly critically ill. Critical care medicine. 2009;37(9):2583-9. 446 31. Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical M, Infectious D. European 447 Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for 448 Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067-79. 449 32. J. van Prehn ER, E.H. Vogelzang, E. Bouza, A. Hristea, B. Guery, M. Krutova, T. Norén, F. 450 Allerberger, J. Coia, A. Goorhuis, T. M. van Rossen, R.E. Ooijevaar, K. Burns, B.R. Scharvik Olesen, S. 451 Tschudin-Sutter, M. H. Wilcox, M. Vehreschild, F. Fitzpatrick, E.J. Kuijper. European Society of Clinical 452 Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for 453 Clostridioides difficile infection in adults. submitted to the ESCMID for (public) approval. 2021. 454 33. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice 455 Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). 456 457 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 458 2018;66(7):e1-e48. 459 34. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. 460 Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J 461 Gastroenterol. 2013;108(4):478-98; quiz 99. Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P, et 462 35. al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol 463 464 Infect. 2006;12 Suppl 6:2-18. 465 36. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies 466 of prognostic factors. Ann Intern Med. 2013;158(4):280-6. 467 37. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst 468 469 Rev. 2013;2:71. 470 38. Alicino C, Giacobbe DR, Durando P, Bellina D, AM DIB, Paganino C, et al. Increasing incidence 471 of Clostridium difficile infections: results from a 5-year retrospective study in a large teaching 472 hospital in the Italian region with the oldest population. Epidemiology and infection. 473 2016;144(12):2517-26. 474 39. Ananthakrishnan AN, Guzman-Perez R, Gainer V, Cai T, Churchill S, Kohane I, et al. Predictors 475 of severe outcomes associated with Clostridium difficile infection in patients with inflammatory 476 bowel disease. Alimentary pharmacology & therapeutics. 2012;35(7):789-95. 477 40. Andrews CN, Raboud J, Kassen BO, Enns R. Clostridium difficile-associated diarrhea: 478 predictors of severity in patients presenting to the emergency department. Canadian journal of 479 gastroenterology = Journal canadien de gastroenterologie. 2003;17(6):369-73. 480 41. Archbald-Pannone LR, McMurry TL, Guerrant RL, Warren CA. Delirium and other clinical 481 factors with Clostridium difficile infection that predict mortality in hospitalized patients. American 482 journal of infection control. 2015;43(7):690-3.

483 Atamna A, Yahav D, Eliakim-Raz N, Goldberg E, Ben-Zvi H, Barsheshet A, et al. The effect of 42. 484 statins on the outcome of Clostridium difficile infection in hospitalized patients. European Journal of 485 Clinical Microbiology and Infectious Diseases. 2016;35(5):779-84.

- 486 Barker AK, Van Galen A, Sethi AK, Shirley D, Safdar N. Tobacco use as a screener for 43. 487 Clostridium difficile infection outcomes. The Journal of hospital infection. 2018;98(1):36-9.
- 488 44. Bauer KA, Johnston JEW, Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, et al. Impact of the 489 NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium 490 difficile infection. Anaerobe. 2017;48:1-6.
- Berry CE, Davies KA, Owens DW, Wilcox MH. Is there a relationship between the presence of 491 45. 492
- the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)?
- 493 European journal of clinical microbiology & infectious diseases : official publication of the European 494 Society of Clinical Microbiology. 2017;36(12):2405-15.

46. Boone JH, Archbald-Pannone LR, Wickham KN, Carman RJ, Guerrant RL, Franck CT, et al.
Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin
and are associated with a higher mortality. European journal of clinical microbiology & infectious
diseases : official publication of the European Society of Clinical Microbiology. 2014;33(6):1045-51.

499 47. Caupenne A, Ingrand P, Ingrand I, Forestier E, Roubaud-Baudron C, Gavazzi G, et al. Acute
 500 Clostridioides difficile Infection in Hospitalized Persons Aged 75 and Older: 30-Day Prognosis and Risk
 501 Factors for Mortality. Journal of the American Medical Directors Association. 2019.

502 48. Charilaou P, Devani K, John F, Kanna S, Ahlawat S, Young M, et al. Acute kidney injury impact 503 on inpatient mortality in Clostridium difficile infection: A national propensity-matched study. Journal 504 of gastroenterology and hepatology. 2018;33(6):1227-33.

505 49. Chintanaboina J, Navabi S, Suchniak-Mussari K, Stern B, Bedi S, Lehman EB, et al. Predictors
506 of 30-Day Mortality in Hospitalized Patients with Clostridium difficile Infection. SouthMedJ.
507 2017;110(8):546-9.

508 50. Clohessy P, Merif J, Post JJ. Severity and frequency of community-onset Clostridium difficile
509 infection on an Australian tertiary referral hospital campus. International Journal of Infectious
510 Diseases. 2014;29:152-5.

511 51. Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, et al. Clostridium difficile fecal 512 toxin level is associated with disease severity and prognosis. United European gastroenterology 513 journal. 2018;6(5):773-80.

514 52. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-515 term mortality in hospitalized patients with clostridium difficile-associated disease. Am J 516 Gastroenterol. 2010;105(9):2040-9.

517 53. De Francesco MA, Lorenzin G, Piccinelli G, Corbellini S, Bonfanti C, Caruso A. Correlation
518 between tcdB gene PCR cycle threshold and severe Clostridium difficile disease. Anaerobe.
519 2019;59:141-4.

520 54. Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. C. difficile colitis--predictors of 521 fatal outcome. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 522 Alimentary Tract. 2010;14(2):315-22.

523 55. Figh ML, Zoog ESL, Moore RA, Dart BWt, Heath G, Butler RM, et al. External Validation of 524 Velazquez-Gomez Severity Score Index and ATLAS Scores and the Identification of Risk Factors

525 Associated with Mortality in Clostridium difficile Infections. The American surgeon.

526 2017;83(12):1347-51.

527 56. Fountain EM, Moses MC, Park LP, Woods CW, Arepally GM. Thrombocytopenia in 528 hospitalized patients with severe clostridium difficile infection. Journal of thrombosis and 529 thrombolysis. 2017;43(1):38-42.

530 57. Fujii L, Fasolino J, Crowell MD, Dibaise JK. Appendectomy and risk of clostridium difficile 531 recurrence. Infectious Diseases in Clinical Practice. 2013;21(1):28-32.

532 58. Hanania A, Jiang ZD, Smiley C, Lasco T, Garey KW, DuPont HL. Fecal calprotectin in the 533 diagnosis of clostridium difficile infection. Infectious Diseases in Clinical Practice. 2016;24(1):31-4.

534 59. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium 535 difficile-associated disease. Emerging infectious diseases. 2009;15(3):415-22.

536 60. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, et al. A portrait of the 537 geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and 538 the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis. 2007;44(2):238-44.

61. Huttunen R, Vuento R, Syrjanen J, Tissari P, Aittoniemi J. Case fatality associated with a

540 hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective 541 population-based study. International journal of infectious diseases : IJID : official publication of the 542 International Society for Infectious Diseases. 2012;16(7):e532-5.

54362.Kassam Z, Cribb Fabersunne C, Smith MB, Alm EJ, Kaplan GG, Nguyen GC, et al. Clostridium544difficile associated risk of death score (CARDS): a novel severity score to predict mortality among

545 hospitalised patients with C. difficile infection. Alimentary pharmacology & therapeutics.

546 2016;43(6):725-33.

547 63. Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, et al. Analysis of 30-548 day mortality for clostridium difficile-associated disease in the ICU setting. Chest. 2007;132(2):418-549 24. 550 64. Khanafer N, Barbut F, Eckert C, Perraud M, Demont C, Luxemburger C, et al. Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe. 551 552 2016;37:43-8. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. The 553 65. 554 epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J 555 Gastroenterol. 2012;107(1):89-95. 556 Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, outcomes, and predictors of 66. 557 mortality in hospitalized adults with Clostridium difficile infection. Internal and emergency medicine. 558 2016;11(5):657-65. 559 Khanna S, Keddis MT, Noheria A, Baddour LM, Pardi DS. Acute kidney injury is an 67. 560 independent marker of severity in Clostridium difficile infection: a nationwide survey. Journal of 561 clinical gastroenterology. 2013;47(6):481-4. 562 68. Kim J, Kim H, Oh HJ, Kim HS, Hwang YJ, Yong D, et al. Fecal Calprotectin Level Reflects the 563 Severity of Clostridium difficile Infection. Annals of laboratory medicine. 2017;37(1):53-7. 564 69. Kim J, Kim Y, Pai H. Clinical Characteristics and Treatment Outcomes of Clostridium difficile 565 Infections by PCR Ribotype 017 and 018 Strains. PloS one. 2016;11(12):e0168849. 566 Kulaylat AS, Buonomo EL, Scully KW, Hollenbeak CS, Cook H, Petri WA, Jr., et al. Development 70. 567 and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With 568 Peripheral Eosinopenia on Admission for Clostridium difficile Infection. JAMA surgery. 569 2018;153(12):1127-33. 570 71. Lee HC, Kim KO, Jeong YH, Lee SH, Jang BI, Kim TN. Clinical Outcomes in Hospitalized Patients 571 with Clostridium difficile Infection by Age Group. The Korean journal of gastroenterology = Taehan 572 Sohwagi Hakhoe chi. 2016;67(2):81-6. 573 72. Leibovici-Weissman Y, Atamna A, Schlesinger A, Eliakim-Raz N, Bishara J, Yahav D. Risk factors 574 for short- and long-term mortality in very old patients with Clostridium difficile infection: A 575 retrospective study. Geriatrics & gerontology international. 2017;17(10):1378-83. 576 73. Mascart G, Delmee M, Van Broeck J, Cytryn E, Karmali R, Cherifi S. Impact of ribotype 027 on 577 Clostridium difficile infection in a geriatric department. European journal of clinical microbiology & 578 infectious diseases : official publication of the European Society of Clinical Microbiology. 579 2013;32(9):1177-82. 580 74. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Health care-associated 581 Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of 582 severe outcome and mortality. Clin Infect Dis. 2010;50(2):194-201. 583 75. Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with 584 complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 585 2011;53(12):1173-8. 586 Ogielska M, Lanotte P, Le Brun C, Valentin AS, Garot D, Tellier AC, et al. Emergence of 76. 587 community-acquired Clostridium difficile infection: the experience of a French hospital and review of 588 the literature. International journal of infectious diseases : IJID : official publication of the 589 International Society for Infectious Diseases. 2015;37:36-41. 590 77. Patel UC, Wieczorkiewicz JT, Tuazon J. Evaluation of advanced age as a risk factor for severe 591 Clostridium difficile infection. Journal of Clinical Gerontology and Geriatrics. 2016;7(1):12-6. 592 78. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-593 associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Cmaj. 2004;171(5):466-72. 594 595 79. Polivkova S, Krutova M, Petrlova K, Benes J, Nyc O. Clostridium difficile ribotype 176 - A

596 predictor for high mortality and risk of nosocomial spread? Anaerobe. 2016;40:35-40.

80. Rao K, Micic D, Chenoweth E, Deng L, Galecki AT, Ring C, et al. Poor functional status as a risk
factor for severe Clostridium difficile infection in hospitalized older adults. Journal of the American
Geriatrics Society. 2013;61(10):1738-42.

81. Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, et al. Clostridium difficile ribotype
027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and
mortality. Clin Infect Dis. 2015;61(2):233-41.

82. Reigadas E, Alcala L, Marin M, Martin A, Iglesias C, Bouza E. Role of binary toxin in the
outcome of Clostridium difficile infection in a non-027 ribotype setting. Epidemiology and infection.
2016;144(2):268-73.

Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant
Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144(5):4339; discussion 9-40.

84. Scardina T, Labuszewski L, Pacheco SM, Adams W, Schreckenberger P, Johnson S. Clostridium
difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in
a non-epidemic setting. Infect Control Hosp Epidemiol. 2015;36(3):280-6.

85. See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, et al. NAP1 strain type predicts
outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58(10):1394-400.

86. Serafino S, Consonni D, Migone De Amicis M, Sisto F, Domeniconi G, Formica S, et al. Clinical
outcomes of Clostridium difficile infection according to strain type. A prospective study in medical
wards. European journal of internal medicine. 2018;54:21-6.

617 87. Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, et al.

618 Clinical factors associated with development of severe-complicated Clostridium difficile infection.

619 Clinical gastroenterology and hepatology : the official clinical practice journal of the American620 Gastroenterological Association. 2013;11(11):1466-71.

88. Starzengruber P, Segagni Lusignani L, Wrba T, Mitteregger D, Indra A, Graninger W, et al.
Severe Clostridium difficile infection: incidence and risk factors at a tertiary care university hospital in

Vienna, Austria. Wiener klinische Wochenschrift. 2014;126(13-14):427-30.

Tamez-Torres KM, Torres-Gonzalez P, Leal-Vega F, Garcia-Alderete A, Lopez Garcia NI,
Mendoza-Aguilar R, et al. Impact of Clostridium difficile infection caused by the NAP1/RT027 strain
on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care
center. International journal of infectious diseases : IJID : official publication of the International

628 Society for Infectious Diseases. 2017;65:44-9.

629 90. Taori SK, Wroe A, Hardie A, Gibb AP, Poxton IR. A prospective study of community-associated
630 Clostridium difficile infections: the role of antibiotics and co-infections. The Journal of infection.
631 2014;69(2):134-44.

532 91. Tschudin-Sutter S, Braissant O, Erb S, Stranden A, Bonkat G, Frei R, et al. Growth Patterns of
Clostridium difficile - Correlations with Strains, Binary Toxin and Disease Severity: A Prospective
Cohort Study. PloS one. 2016;11(9):e0161711.

635 92. van der Wilden GM, Chang Y, Cropano C, Subramanian M, Schipper IB, Yeh DD, et al.

Fulminant Clostridium difficile colitis: prospective development of a risk scoring system. The journalof trauma and acute care surgery. 2014;76(2):424-30.

638 93. Vojtilova L, Freibergerova M, Jurankova J, Bortlicek Z, Husa P. Epidemiological factors
639 influencing the development of relapsing and severe Clostridium difficile infection. Epidemiologie,
640 mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske

641 spolecnosti JE Purkyne. 2014;63(1):27-35.

642 94. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, et al. Clostridium difficile Ribotype Does Not
643 Predict Severe Infection. Clin Infect Dis. 2012;55(12):1661-8.

644 95. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, et al. Relationship between

bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis.
2013;56(11):1589-600.

647 96. Wilson V, Cheek L, Satta G, Walker-Bone K, Cubbon M, Citron D, et al. Predictors of death 648 after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the 649 United Kingdom. Clin Infect Dis. 2010;50(12):e77-81. 650 97. Xu Q, Chen Y, Gu S, Lv T, Zheng B, Shen P, et al. Hospital-acquired Clostridium difficile 651 infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university 652 hospital. Scientific reports. 2017;7(1):9645. 653 98. Yong FA, Alvarado AM, Wang H, Tsai J, Estes NC. Appendectomy: a risk factor for colectomy 654 in patients with Clostridium difficile. American journal of surgery. 2015;209(3):532-5. 655 99. Miller R, Morillas JA, Brizendine KD, Fraser TG. Predictors of Clostridioides difficile Infection-656 Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin 657 Enzyme Immunoassay-Negative Patients. J Clin Microbiol. 2020;58(3). 658 Menon A, Perry DA, Motyka J, Weiner S, Standke A, Penkevich A, et al. Changes in the 100. 659 Association between Diagnostic Testing Method, PCR Ribotype, and Clinical Outcomes from 660 Clostridioides difficile Infection: One Institution's Experience. Clin Infect Dis. 2020. 661 101. Korac M, Rupnik M, Nikolic N, Jovanovic M, Tosic T, Malinic J, et al. Clostridioides difficile ribotype distribution in a large teaching hospital in Serbia. Gut Pathog. 2020;12:26. 662 663 102. Essrani R, Saturno D, Mehershahi S, Essrani RK, Hossain MR, Ravi SJK, et al. The Impact of 664 Appendectomy in Clostridium difficile Infection and Length of Hospital Stay. Cureus. 665 2020;12(9):e10342. Choi B, Wong KK, Dunn AN, Butler R, Fraser TG, Procop GW, et al. Real-time polymerase 666 103. 667 chain reaction (PCR) cycle threshold and Clostridioides difficile infection outcomes. Infect Control 668 Hosp Epidemiol. 2021:1-7. 669 104. Avni T, Hammud H, Itzhaki O, Gafter-Gvili A, Rozen-Zvi B, Ben-Zvi H, et al. The significance of 670 acute kidney injury in Clostridioides difficile infection. Int J Clin Pract. 2021;75(3). Mendez-Bailon M, Jimenez-Garcia R, Hernandez-Barrera V, Miguel-Diez J, Miguel-Yanes JM, 671 105. 672 Munoz-Rivas N, et al. Heart Failure Is a Risk Factor for Suffering and Dying of Clostridium difficile 673 Infection. Results of a 15-Year Nationwide Study in Spain. J Clin Med. 2020;9(3). 674 106. Chiang HY, Huang HC, Chung CW, Yeh YC, Chen YC, Tien N, et al. Risk prediction for 30-day 675 mortality among patients with Clostridium difficile infections: a retrospective cohort study. 676 Antimicrob Resist Infect Control. 2019;8:175. 677 107. Vata A, Miftode IL, Dorneanu OS, Vata LG, Miftode D, Trifan A, et al. CLOSTRIDIUM DIFFICILE 678 INFECTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. THE EXPERIENCE OF AN INFECTIOUS 679 DISEASES HOSPITAL FROM NORTH-EASTERN ROMANIA. Med-Surg J. 2019;123(3):506-12.

- Mani NS, Lynch JB, Fang FC, Chan JD. Risk Factors for BI/NAP1/027 Clostridioides difficile
 Infections and Clinical Outcomes Compared With Non-NAP1 Strains. Open Forum Infect Dis.
 2019;6(12):4.
- 683 109. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and
- outcomes in Clostridium difficile infection: a population-based study. Mayo Clinic proceedings.
 2012;87(7):636-42.
- Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in
 outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic
 validation study of C difficile infection. The Lancet Infectious diseases. 2013;13(11):936-45.
- 689 111. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al.
- 690 Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63-73.
- 691 112. Argamany JR, Lee GC, Duhon BD, Zeidan AR, Young EH, Reveles KR. A possible association
- between statin use and improved Clostridioides difficile infection mortality in veterans. PloS one.
 2019;14(5):e0217423.
- 694113.Leal J, Ronksley P, Henderson EA, Conly J, Manns B. Predictors of mortality and length of stay
- in patients with hospital-acquired Clostridioides difficile infection: a population-based study in
 Alberta, Canada. The Journal of hospital infection. 2019;103(1):85-91.

697 114. Nagayoshi Y, Yamamoto K, Sato S, Suyama N, Izumikawa T, Izumikawa K, et al. Clinical 698 significance of a positive Clostridioides difficile glutamate dehydrogenase test on the outcomes of 699 hospitalized older patients. Geriatrics & gerontology international. 2020;20(12):1138-44. 115. 700 Patel H, Makker J, Vakde T, Shaikh D, Badipatla K, Dunne J, et al. Nonsteroidal Anti-701 Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with Clostridium difficile 702 Infection. Clinical and experimental gastroenterology. 2019;12:449-56. 703 116. Tay HL, Chow A, Ng TM, Lye DC. Risk factors and treatment outcomes of severe Clostridioides 704 difficile infection in Singapore. Scientific reports. 2019;9(1):13440. 705 117. Origuen J, Orellana MA, Fernandez-Ruiz M, Corbella L, San Juan R, Ruiz-Ruigomez M, et al. 706 Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in 707 Clostridium difficile Infection: a Retrospective Cohort Study. J Clin Microbiol. 2019;57(2).

Milenkovic B, Suljagic V, Peric A, Dragojevic-Simic V, Tarabar O, Milanovic M, et al. Outcomes
of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary
hospital: a prospective cohort study. Eur J Hosp Pharm. 2021.

119. Lopez-Cardenas S, Torres-Martos E, Mora-Delgado J, Sanchez-Calvo JM, Santos-Pena M,
Zapata Lopez A, et al. The prognostic value of toxin B and binary toxin in Clostridioides difficile
infection. Gut Microbes. 2021:1-8.

120. Enoch DA, Murray-Thomas T, Adomakoh N, Dedman D, Georgopali A, Francis NA, et al. Risk
of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection:
a retrospective observational database study in England. The Journal of hospital infection.

717 2020;106(4):793-803.

121. Carlson TJ, Endres BT, Le Pham J, Gonzales-Luna AJ, Alnezary FS, Nebo K, et al. Eosinopenia
and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection.
Open Forum Infect Dis. 2020;7(1):ofz552.

122. Abdelfatah M, Nayfe R, Nijim A, Enriquez K, Ali E, Watkins RR, et al. Factors Predicting

Recurrence of Clostridium difficile Infection (CDI) in Hospitalized Patients: Retrospective Study of
 More Than 2000 Patients. J Investig Med. 2015;63(5):747-51.

123. Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Clostridioides
difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care
settings. Am J Health Syst Pharm. 2019;76(9):581-90.

124. Avni T, Babitch T, Ben-Zvi H, Hijazi R, Ayada G, Atamna A, et al. Clostridioides difficile
infection in immunocompromised hospitalized patients is associated with a high recurrence rate. Int J
Infect Dis. 2020;90:237-42.

730 125. Carpenter BP, Hennessey EK, Bryant AM, Khoury JA, Crannage AJ. Identification of Factors

731 Impacting Recurrent Clostridium difficile Infection and Development of a Risk Evaluation Tool. J
 732 Pharm Pharm Sci. 2016;19(3):349-56.

126. Dharbhamulla N, Abdelhady A, Domadia M, Patel S, Gaughan J, Roy S. Risk Factors Associated
With Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11(1):1-6.

735 127. Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR.

- Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124(11):1081e1-7.
- 128. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Predictors of first
- recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis.2012;55 Suppl 2:S77-87.
- 741 129. Falcone M, Tiseo G, Iraci F, Raponi G, Goldoni P, Delle Rose D, et al. Risk factors for

recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clin
 Microbiol Infect. 2019;25(4):474-80.

130. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for

recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11):1794-801.

- 131. Fujii LF, J. Crowell, M. DiBaise, K. Appendectomy and Risk of Clostridium difficile Recurrence.
- 748 Infectious Diseases in Clinical Practice. 2013;21(1):28-32.

749 132. Im GY, Modayil RJ, Lin CT, Geier SJ, Katz DS, Feuerman M, et al. The appendix may protect against Clostridium difficile recurrence. Clinical gastroenterology and hepatology : the official clinical 750 751 practice journal of the American Gastroenterological Association. 2011;9(12):1072-7. 752 133. Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large 753 754 hospital-based administrative dataset. J Infect Chemother. 2019;25(8):615-20. 755 134. Lavergne V, Beausejour Y, Pichette G, Ghannoum M, Su SH. Lymphopenia as a novel marker 756 of Clostridium difficile infection recurrence. The Journal of infection. 2013;66(2):129-35. 757 135. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for 758 recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772-8. 759 136. Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, et al. Effect of age on 760 treatment outcomes in Clostridium difficile infection. Journal of the American Geriatrics Society. 761 2013;61(2):222-30. Lupse M, Flonta M, Cioara A, Filipescu I, Todor N. Predictors of first recurrence in Clostridium 762 137. 763 difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral 764 center. J Gastrointestin Liver Dis. 2013;22(4):397-403. 765 138. Marincu I, Bratosin F, Vidican I, Cerbu B, Turaiche M, Tirnea L, et al. Predictive Factors for the 766 First Recurrence of Clostridioides difficile Infection in the Elderly from Western Romania. Medicina 767 (Kaunas). 2020;56(9). McDonald EG, Milligan J, Frenette C, Lee TC. Continuous Proton Pump Inhibitor Therapy and 768 139. 769 the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern Med. 2015;175(5):784-770 91. 771 140. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent 772 Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 773 1999;20(1):43-50. 774 141. Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y. Risk factors for recurrent Clostridium 775 difficile infection in a tertiary hospital in Israel. European journal of clinical microbiology & infectious 776 diseases : official publication of the European Society of Clinical Microbiology. 2018;37(7):1281-8. 777 142. Negrut N, Bungau S, Behl T, Khan SA, Vesa CM, Bustea C, et al. Risk Factors Associated with 778 Recurrent Clostridioides difficile Infection. Healthcare. 2020;8(3):12. 779 143. Origüen J, Orellana M, Fernández-Ruiz M, Corbella L, San Juan R, Ruiz-Ruigómez M, et al. 780 Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in 781 Clostridium difficile Infection: a Retrospective Cohort Study. J Clin Microbiol. 2019;57(2). 782 144. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after 783 treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591-7. 784 145. Rao K, Higgins PDR, Young VB. An Observational Cohort Study of Clostridium difficile Ribotype 785 027 and Recurrent Infection. mSphere. 2018;3(3). Rodriguez-Pardo D, Almirante B, Bartolome RM, Pomar V, Mirelis B, Navarro F, et al. 786 146. 787 Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: 788 results of a hospital-based study in Barcelona, Spain. J Clin Microbiol. 2013;51(5):1465-73. 789 Rotramel A, Poritz LS, Messaris E, Berg A, Stewart DB. PPI therapy and albumin are better 147. 790 predictors of recurrent Clostridium difficile colitis than choice of antibiotics. Journal of 791 gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 792 2012;16(12):2267-73. 793 148. van Beurden YH, Nezami S, Mulder CJJ, Vandenbroucke-Grauls C. Host factors are more 794 important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics. 795 Clin Microbiol Infect. 2018;24(1):85 e1- e4. 796 Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER. Risk factors for recurrent Clostridium 149. 797 difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a

retrospective cohort study. BMC Infect Dis. 2014;14:306.

To. Cadena J, Thompson GR, 3rd, Patterson JE, Nakashima B, Owens A, Echevarria K, et al. Clinical
predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci. 2010;339(4):3505.

Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA. Diabetes mellitus as a risk factor
 for recurrence of Clostridium difficile infection in the acute care hospital setting. American journal of
 infection control. 2011;39(3):194-8.

Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent
Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective,
randomized, double-blinded trial. Clin Infect Dis. 1997;24(3):324-33.

808 153. Ryu HS, Kim YS, Seo GS, Lee YM, Choi SC. Risk Factors for Recurrent Clostridium difficile
809 Infection. Intest Res. 2012;10(2):176-82.

810 154. Golan Y, DuPont HL, Aldomiro F, Jensen EH, Hanson ME, Dorr MB. Renal Impairment, C.
811 difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data

812 From 2 Randomized Clinical Trials. Open Forum Infect Dis. 2020;7(7):ofaa248.

813 155. Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump
814 inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients
815 with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015;2(1):e000028.

816 156. Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, et al. Bezlotoxumab for
817 Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
818 Clin Infect Dis. 2018;67(5):649-56.

157. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, et al. Fidaxomicin versus

vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.Clin Infect Dis. 2012;55 Suppl 2:S93-103.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for
Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-17.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus
vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-31.

160. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus
vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind,
non-inferiority, randomised controlled trial. The Lancet Infectious diseases. 2012;12(4):281-9.

161. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
comorbidity in longitudinal studies: development and validation. Journal of chronic diseases.
1987;40(5):373-83.

Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and
 mortality in Clostridium difficile infection: a systematic review. PloS one. 2014;9(6):e98400.

163. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV, et al. Risk factors for
recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp
Epidemiol. 2015;36(4):452-60.

837 164. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent
838 Clostridium difficile infection. The Journal of hospital infection. 2008;70(4):298-304.

839 165. Zhang VRY, Woo ASJ, Scaduto C, Cruz MTK, Tan YY, Du H, et al. Systematic review on the

840 definition and predictors of severe Clostridiodes difficile infection. Journal of gastroenterology and 841 hepatology. 2021;36(1):89-104.

B42 166. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence
risk research. Jama. 2011;305(8):822-3.

844 167. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, Mahaparn P,

845 Bruminhent J. The Risks of Incident and Recurrent Clostridium difficile-Associated Diarrhea in Chronic

Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Digestive diseases and sciences. 2015;60(10):2913-22.

848 168. Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in

patients with inflammatory bowel disease. Current opinion in gastroenterology. 2021;37(4):336-43.

- 850 169. Beauregard-Paultre C, Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold W, et al.
- External validation of clinical prediction rules for complications and mortality following Clostridioidesdifficile infection. PloS one. 2019;14(12):e0226672.
- 853 170. van Beurden YH, Hensgens MPM, Dekkers OM, Le Cessie S, Mulder CJJ, Vandenbroucke-
- 854 Grauls C. External Validation of Three Prediction Tools for Patients at Risk of a Complicated Course of 855 Clostridium difficile Infection: Disappointing in an Outbreak Setting. Infect Control Hosp Epidemiol.
- 855 Clostificitini difficile intection. Disappointing in an Outbreak Setting. Infect Control Hosp Epidemiol.856 2017;38(8):897-905.
- 857 171. van Rossen TM, van Dijk LJ, Heymans MW, Dekkers OM, Vandenbroucke-Grauls C, van
- 858 Beurden YH. External validation of two prediction tools for patients at risk for recurrent Clostridioides
- difficile infection. Therapeutic advances in gastroenterology. 2021;14:1756284820977385.
- 860

861 Supplementary data

- 862 PICO's
- 863 Two PICO's were formulated:
- 864 Prognosis severe CDI:
- 865 P: patients with CDI
- 866 I: presence of clinical and laboratory parameters
- 867 C: absence of clinical and laboratory parameters
- 868 O: severe CDI
- 869 Prognosis recurrent CDI:
- 870 P: patients with CDI
- 871 I: presence of clinical and laboratory parameters
- 872 C: absence of clinical and laboratory parameters
- 873 O: recurrent CDI
- 874 Literature search prognosis severe CDI Pubmed
- 875 (("Clostridium difficile Infection"[tw] OR "Clostridium difficile Infections"[tw] OR "C difficile
- 876 Infection"[tw] OR "C difficile Infections"[tw] OR "clostridioides difficile infection"[tw] OR
- 877 (("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C difficile"[ti] OR "c diff"[ti] OR
- 878 "clostridioides difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
- 879 "Clostridium Infection"[ti])) OR (("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C
- 880 difficile"[ti] OR "difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
- 881 "Clostridium Infection"[ti] OR "Infection"[majr] OR "infection"[ti] OR "infections"[ti] OR infect*[ti] OR
- 882 "inflammation"[ti] OR inflammat*[ti] OR "Enterocolitis"[majr] OR "Enterocolitis"[ti] OR "colitis"[ti] OR
- 883 "Digestive System Diseases"[majr])))
- 884 AND
- 885 ("Prognosis"[Mesh] OR prognos*[tw] OR "prognostic factor"[tw] OR "prognostic factors"[tw] OR
- 886 "clinical parameter"[tw] OR "clinical parameters"[tw] OR "laboratory parameter"[tw] OR "laboratory
- parameters"[tw] OR "Age Factors"[mesh] OR "Age Factor"[tw] OR "Age Factors"[tw] OR "Age"[tiab]
- 888 OR "Age Reporting"[tw] OR "Leukocytosis"[Mesh] OR "Leukocytosis"[tw] OR "Pleocytosis"[tw] OR
- 889 "leucocytosis"[tw] OR "Leukemoid Reaction"[tw] OR "Lymphocytosis"[tw] OR (decreas*[tw] AND
- 890 ("Serum Albumin"[mesh] OR "blood albumin"[tw] OR "serum albumin"[tw])) OR (("rise"[tw] OR

- 891 "rising"[tw] OR rise*[tw] OR increas*[tw]) AND ("serum creatinine"[tw] OR
- 892 "Creatinine/blood"[mesh])) OR "severe underlying disease"[tw] OR "severe underlying diseases"[tw]
- 893 OR "severe underlying illness" [tw] OR "severe underlying illnesses" [tw] OR "severe underlying
- 894 condition"[tw] OR "severe underlying conditions"[tw] OR "Immunologic Deficiency
- Syndromes" [Mesh] OR "Immunologic Deficiency" [tw] OR "Immune Deficiency" [tw] OR
- 896 "immunodeficiency"[tw] OR "Immunologic Deficiencies"[tw] OR "Immune Deficiencies"[tw] OR
- 897 "immunodeficiencies"[tw] OR "Immunocompromised Host"[Mesh] OR "Immunocompromised"[tw]
- 898 OR (strain*[tw] AND ribotype*[tw]))

899 AND

- 900 ("severe clostridium difficile"[tw] OR "severe cdi"[tw] OR "severe cd"[tw] OR "disease severity"[tw]
- 901 OR "illness severity"[tw] OR "severity of disease"[tw] OR "severity of illness"[tw] OR "severe"[tw] OR
- 902 "severity"[tw] OR sever*[tw])

903 **NOT**

- 904 (("Case Reports"[ptyp] OR "case report"[ti]) NOT ("Review"[ptyp] OR "review"[ti] OR "Clinical
- 905 Study"[ptyp] OR "trial"[ti] OR "RCT"[ti])) NOT ("Animals"[mesh] NOT "Humans"[mesh])

906 **AND**

907 english[la])

908 Literature search prognosis recurrent CDI - Pubmed:

909 (("Clostridium difficile Infection"[tw] OR "Clostridium difficile Infections"[tw] OR "C difficile

910 Infection"[tw] OR "C difficile Infections"[tw] OR "clostridioides difficile infection"[tw] OR

- 911 (("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C difficile"[ti] OR "c diff"[ti] OR
- 912 "clostridioides difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
- 913 "Clostridium Infection"[ti])) OR (("Clostridium difficile"[majr] OR "Clostridium difficile"[ti] OR "C
- 914 difficile"[ti] OR "difficile"[ti]) AND ("Clostridium Infections"[majr] OR "Clostridium Infection"[ti] OR
- 915 "Clostridium Infection"[ti] OR "Infection"[majr] OR "infection"[ti] OR "infections"[ti] OR infect*[ti] OR
- 916 "inflammation"[ti] OR inflammat*[ti] OR "Enterocolitis"[majr] OR "Enterocolitis"[ti] OR "colitis"[ti] OR
- 917 "Digestive System Diseases"[majr])))

918 AND

- 919 ("Prognosis"[Mesh] OR prognos*[tw] OR "prognostic factor"[tw] OR "prognostic factors"[tw] OR
- 920 "clinical parameter"[tw] OR "clinical parameters"[tw] OR "laboratory parameter"[tw] OR "laboratory
- 921 parameters"[tw] OR "Age Factors"[mesh] OR "Age Factor"[tw] OR "Age Factors"[tw] OR "Age"[tiab]
- 922 OR "Age Reporting" [tw] OR "severe underlying disease" [tw] OR "severe underlying diseases" [tw] OR
- 923 "severe underlying illness" [tw] OR "severe underlying illnesses" [tw] OR "severe underlying
- 924 condition"[tw] OR "severe underlying conditions"[tw] OR "Immunologic Deficiency
- 925 Syndromes"[Mesh] OR "Immunologic Deficiency"[tw] OR "Immune Deficiency"[tw] OR
- 926 "immunodeficiency"[tw] OR "Immunologic Deficiencies"[tw] OR "Immune Deficiencies"[tw] OR
- 927 "immunodeficiencies"[tw] OR "Immunocompromised Host"[Mesh] OR "Immunocompromised"[tw]
- 928 OR (strain*[tw] AND ribotype*[tw]) OR ((continued use*[tw] OR continuing use*[tw] OR prolonged
- 929 use*[tw]) AND (antibiotic*[tw] OR antibacterial*[tw] OR anti-biotic*[tw] OR anti-bacterial*[tw])) OR

- 930 "renal failure"[tw] OR "kidney failure"[tw] OR "Renal Insufficiency"[Mesh] OR "Renal
- 931 Insufficiency"[tw] OR "Kidney Insufficiency"[tw] OR "kidney injury"[tw] OR "renal injury"[tw] OR
- 932 previous infection*[tw] OR "Proton Pump Inhibitors"[Mesh] OR "Proton Pump
- 933 Inhibitors" [Pharmacological Action] OR "Proton Pump Inhibitors" [tw] OR "Proton Pump
- 934 Inhibitor"[tw] OR "initial severity"[tw] OR "initial disease severity"[tw] OR "initial illness severity"[tw]
- 935 OR (strain*[tw] AND ribotype*[tw]))
- 936 AND
- 937 ("recurrent clostridium difficile"[tw] OR "recurrent cdi"[tw] OR "recurrent cd"[tw] OR
- 938 "Recurrence"[Mesh] OR recurr*[tw])
- 939 **NOT**
- 940 (("Case Reports"[ptyp] OR "case report"[ti]) NOT ("Review"[ptyp] OR "review"[ti] OR "Clinical
- 941 Study"[ptyp] OR "trial"[ti] OR "RCT"[ti])) NOT ("Animals"[mesh] NOT "Humans"[mesh])
- 942 AND
- 943 english[la])